RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale

[1]  R. Iijima,et al.  RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale , 2013, Lipids in Health and Disease.

[2]  S. Kihara,et al.  Diagnostic criteria for dyslipidemia. , 2013, Journal of atherosclerosis and thrombosis.

[3]  S. Saydah,et al.  The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010 , 2013, Diabetes Care.

[4]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[5]  T. Miida,et al.  Small dense LDL: An emerging risk factor for cardiovascular disease. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[6]  T. Dayspring,et al.  Ezetimibe therapy: mechanism of action and clinical update , 2012, Vascular health and risk management.

[7]  S. Garg,et al.  Small dense LDL: risk factor for coronary artery disease (CAD) and its therapeutic modulation. , 2012, Indian journal of biochemistry & biophysics.

[8]  Y. Yamasaki,et al.  Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). , 2011, The Journal of clinical endocrinology and metabolism.

[9]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[10]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[11]  M. Flather.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[12]  Lawrence A Leiter,et al.  Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither , 2010, Diabetes, obesity & metabolism.

[13]  T. Ninomiya,et al.  Impact of Glucose Tolerance Status on Development of Ischemic Stroke and Coronary Heart Disease in a General Japanese Population: The Hisayama Study , 2010, Stroke.

[14]  MasayoFukuhara,et al.  Impact of Glucose Tolerance Status on Development of Ischemic Stroke and Coronary Heart Disease in a General Japanese Population , 2010 .

[15]  T. Funahashi,et al.  Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. , 2007, Journal of atherosclerosis and thrombosis.

[16]  T. Funahashi,et al.  Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. , 2007, Journal of atherosclerosis and thrombosis.

[17]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[18]  B. Hawes,et al.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Lewin,et al.  Efficacy and safety of ezetimibe co‐administered with simvastatin in thiazolidinedione‐treated type 2 diabetic patients , 2005, Diabetes, obesity & metabolism.

[20]  S. Koba,et al.  Clinical Significance of Small Dense Low-Density Lipoprotein Cholesterol Levels Determined by the Simple Precipitation Method , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[21]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[22]  R. Suresh,et al.  Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. , 2003, European heart journal.

[23]  R. Suresh,et al.  Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. , 2003, The American journal of cardiology.

[24]  R. Suresh,et al.  Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[25]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[26]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[27]  I. Stratton,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[28]  T. Murohara,et al.  Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. , 2012, Journal of cardiology.

[29]  R. Collins,et al.  Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial , 2012, Drugs.

[30]  Chie Aoki,et al.  Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. , 2011, Endocrine journal.

[31]  A. Pontiroli,et al.  Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). , 2010 .

[32]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[33]  武井泉,et al.  United Kingdom Prospective Diabetes Study (UKPDS) , 1999 .

[34]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .